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Background: Progesterone is emerging as an important protective agent against various injuries 
to the nervous system. Neuroprotective and remyelinating effects have been documented for this 
neurosteroid, which is synthesized by, and acts on, the central and peripheral nervous systems. 
Neuropathic pain is a severe, persistent condition that is generally resistant to treatment, and 
poses major personal, social, and economic burdens. The purpose of this study was to determine 
if single-dose or repeated progesterone administration would alleviate tactile hypersensitivity 
in a rat model of neuropathic pain, and to determine if early versus late initiation of treatment 
has an effect on the outcome.
Methods: Rats were unilaterally implanted with a polyethylene cuff around the sciatic nerve, 
and sensitivity to von Frey filament stimulation was measured over approximately 12 weeks.
Results: Rats given progesterone starting one hour after cuff implantation, and daily until day 4, 
exhibited tactile hypersensitivity similar to that of vehicle-treated rats for the duration of the 
study. When progesterone was started one hour after cuff implantation and given daily until 
day 10, rats exhibited no tactile hypersensitivity in the later part of the study, after treatment had 
stopped. When progesterone treatment was initiated at 20 days, once the model had been fully 
established, and given daily for 4 or even 11 days, no differences in withdrawal thresholds were 
observed compared with controls. Progesterone did not have any effect on withdrawal thresholds 
when given as a single dose, as measured at 30, 60 and 90 minutes after administration.
Conclusion: These results indicate that progesterone, when administered immediately after 
nerve injury, and for a sufficient period of time, can prevent the development of neuropathic 
pain, and may offer new strategies for the treatment of this highly debilitating condition.
Keywords: progesterone, neurosteroid, neuropathic pain, peripheral neuropathy, recovery, 
neuroprotection
Introduction
Neuropathic pain is a chronic, debilitating condition that results from various injuries 
and diseases of the central and peripheral nervous systems, and has been described as 
a neurodegenerative disease.1,2 Such insults to the nervous system may include, but are 
not limited to, nerve trauma, amputation, nerve compression or entrapment, diabetes, 
stroke, demyelinating disorders, nerve tumors, viral infections, and chemotherapy. 
Current pooled estimates of the incidence of neuropathic pain suggest that it affects 
3% of the population.3 Although heterogeneous in origin, the experience of neuropathic 
pain is described in similar terms, such as burning, shock-like, pricking, tingling, 
or cold.4 It is often severe and unrelenting, and is generally undertreated with the 
pharmacological and surgical interventions that are presently available.5 Neuropathic 
pain, therefore, has a profound negative impact on the life of the sufferer and poses an Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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economic burden due to high health care costs and disability.6 
The undertreatment of this devastating condition indicates 
that new and effective evidence-based treatment options are 
urgently needed.
It has been shown that progesterone reduces neuronal 
damage and improves functional outcome in animal models 
of traumatic brain injury. Following frontal aspiration 
lesion, pseudopregnant female rats showed less impairment 
in spatial learning than did normally cycling females,7 and 
virtually no edema after contusion injury to the medial frontal 
cortex.8 Further investigation showed that progesterone 
was the critical factor in reducing edema.8 Treatment with 
progesterone after contusion injury also decreases edema,9 
improves Morris water maze performance, and reduces 
secondary neuronal loss.10
Progesterone has been reported to have neuroprotective 
effects in animal models of several other types of neurological 
disorders. In a rat model of stroke, where the middle cerebral 
artery was occluded, treatment with progesterone decreased 
cerebral infarct volume, edema, inflammation, neuronal death, 
and increased neurological function.11–16 Neuroprotective 
effects were also observed with progesterone administration 
in models of spinal cord injury,17,18 a genetic model of 
spinal cord motor neuron degeneration (Wobbler mouse),19 
and in experimental allergic encephalomyelitis, an animal 
model of multiple sclerosis, as described by El-Etr et al.20 
The proposed mechanisms by which progesterone exerts 
these neuroprotective effects include reduction of edema, 
oxidative stress, and apoptosis, as well as reduction of 
inflammation by inhibiting microglial cell activation and 
production of proinflammatory cytokines.21,22
The results of human studies have been consistent with 
the findings from animal studies. In ProTECT (a randomized 
controlled trial of experimental clinical treatment with 
progesterone for acute traumatic brain injury), there was 
a 50% lower 30-day mortality rate in subjects receiving 
progesterone treatment after acute traumatic brain injury 
compared with those randomized to receive the placebo. 
The survivors who sustained moderate injury and received 
progesterone had better outcomes and were less disabled 
than those with moderate injury receiving the placebo.23 
A second randomized controlled trial24 showed that, after 
severe traumatic brain injury, the progesterone-treated group 
had better outcomes at the three- and six-month follow-up, 
and a lower mortality rate after six months. Two Phase III 
clinical trials were scheduled to begin in 2010.25 Also, there 
is a decreased relapse rate in women with multiple sclerosis 
during pregnancy, especially during the third trimester, 
suggesting a possible protective role for progesterone in 
multiple sclerosis.26,27
Therefore, the rationale for the present study is that 
because progesterone plays a protective role following 
nerve injury, it may be effective in alleviating the resulting 
pain scores in a rat model of peripheral neuropathy. It was 
hypothesized that chronic progesterone treatment will delay 
or limit the development of hypersensitivity in a rat model 
of neuropathic pain. The model used here consists of fitting 
a 2 mm-long polyethylene cuff around one sciatic nerve 
of the rat, based on the method described by Mosconi and 
Kruger.28 Hypersensitivity was measured using calibrated 
von Frey filaments according to the method described by 
Chaplan et al.29 Because common clinical practice indicates 
that neuroprotective interventions should be performed 
immediately after injury, it was further hypothesized that 
early progesterone treatment would be more effective than 
treatment initiated after pain hypersensitivity has been 
established. To compare early versus late treatment, rats 
were given progesterone starting immediately after cuff 
implantation surgery, and continued daily until day 4 or day 10, 
or progesterone was started on day 20 after cuff implantation, 
and continued daily until day 23 or day 30. Effects of a single 
dose of progesterone on hypersensitivity were also tested 
at 30, 60, and 90 minutes after administration.
Materials and methods
Animals
Male Sprague-Dawley rats (Charles River, QC) were housed 
in pairs and maintained on a 12-hour light cycle, with food 
and water available ad libitum. All procedures complied 
with the Guidelines for the Care and Use of Experimental 
Animals issued by the Canadian Council on Animal Care. All 
procedures were also approved by the Animal Research Eth-
ics Board (McMaster University, Hamilton, ON). For three 
days prior to any behavioral testing, the rats were kept in their 
home cages in the testing room for approximately three hours 
each day. During this time, rats were intermittently handled 
by the investigator, and introduced to the testing chamber for 
a brief period of time (approximately 15 minutes).
Model induction
The method of sciatic nerve cuffing was based on that 
described by Mosconi and Kruger.28 Rats were anesthetized 
with a combination of ketamine (Ketalean® 5 mg/100 g; 
Bimeda-MTC Animal Health Inc, Cambridge, ON), xylazine 
(Rompun® 0.5 mg/100 g; Bayer HealthCare, Toronto, ON), 
and acepromazine (Atravet® 0.1 mg/100 g; Ayerst Veterinary Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Laboratories, Guelph, ON) given intraperitoneally. The 
left sciatic nerve was exposed after blunt dissection of 
the overlying muscle and freed from the surrounding 
tissue. A cuff made of a 2-mm segment of polyethylene 
tubing (Intramedic PE-90; Clay Adams, Division of 
Becton Dickinson, Parsippany, NJ) slit longitudinally was 
fitted around the nerve. Subsequently, the muscle was 
sutured, and the skin closed using suture clips. Antibiotic 
ointment (Furacin®, nitrofurazone 0.2%; Vetoquinol N.-A. 
Inc, Lavaltrie, QC) was applied over the wound, and 
0.03 mL of antibiotic (Tribrissen® 24%; trimethoprim-
sulfadiazine; Schering Canada Inc, Pointe Claire, QC) was 
injected subcutaneously. Animals were given 1 mL saline 
subcutaneously; ocular lubricant, and placed under a heating 
lamp until they recovered from the anesthetic, and were then 
returned to their home cages.
Paw withdrawal thresholds
The testing chamber consisted of a 30 × 30 × 30 cm 
Plexiglas® box with a clear Plexiglas® floor based on 
the method described by Pitcher et al.30 The floor contained 
0.5 cm diameter holes that were spaced 1.5 cm apart, and 
was positioned over a mirror tilted to 45° which allowed 
an unobstructed view of the rat paws. Each rat was placed 
with its cage mate in the testing chamber and allowed to 
acclimatize for 30 minutes prior to testing. Both rats were in 
the chamber during testing. von Frey filaments (Stoelting Co, 
Wood Dale, IL) were applied to the soft tissue of the plantar 
surface of the hind paw to determine the withdrawal threshold, 
according to the “up–down method”. The first filament 
applied corresponded to a force of 2 g. Each filament was 
applied three times, at intervals of three seconds. If a negative 
response (no movement) was observed, the filament exerting 
the next greater force was applied. If a positive response (paw 
withdrawal) was observed, the next filament of lesser force 
was used next. A 50% response threshold was calculated 
according to the response pattern observed, as described by 
Chaplan et al.29 The maximum score possible was 15 g, and 
the minimum was 0.25 g.
Drug and time of administration
Progesterone (4-pregnene-3,20-dione; Sigma Chemical Co, 
St Louis, MO) was given at a dose of 4 mg/kg, dissolved in 
peanut oil and administered intraperitoneally at a volume of 
0.1 mL/100 g body weight. The progesterone solution was 
freshly prepared on each day of injection. The structure of 
the progesterone used was identical to that of progesterone 
naturally occurring in humans. This dose of progesterone 
was chosen based on previously published reports showing 
that this was a relatively low dose that was effective with 
repeated treatment in other models of nerve injury.9,10,31,32 
Control group rats were given peanut oil 0.1 mL/100 g 
intraperitoneally.
Repeated treatment
Drug or vehicle was administered in one of two types of regi-
mens, ie, during the onset phase of model development, termed 
“early treatment”, and after the model had fully established, 
termed “late treatment”. These times were chosen to clarify 
the possible effects of repeated progesterone administration 
during the onset phase and during the   maintenance phase 
of the model. For the early treatment groups, progesterone 
was administered starting approximately one hour after cuff 
implantation surgery, and continued once daily for 4 (PROG 
d0–4) or 10 (PROG d0–10) additional days. The early vehicle 
groups were given peanut oil injections according to the same 
schedule (VEH d0–4 and VEH d0–10).
For the late treatment groups, day 20 was chosen as the 
start of treatment because our previous studies have indicated 
that the model is fully established and stable by this time. 
Progesterone was administered daily on days 20–23 after 
surgery (PROG d20–23) or on days 20–30 after surgery 
(PROG d20–30). The late vehicle groups were given peanut oil 
injections according to the same schedule (VEH d20–23 and 
VEH d20–30). For repeated treatment, injections were always 
given after measurement of paw withdrawal thresholds.
single-dose treatment
Baseline paw withdrawal thresholds were measured, and 
rats were injected with the peanut oil vehicle. Withdrawal 
thresholds were measured again at 30, 60, and 90 minutes after 
injection. The following day, baseline readings were taken, 
and the rats were injected with progesterone. Withdrawal 
thresholds were measured at 30, 60, and 90 minutes. Single-
dose testing was done early (days 3 and 4) and late (days 87 
and 88) after cuff implantation. For the early treatment group, 
vehicle was given on day 3 and progesterone on day 4 after 
cuff implantation. For the late treatment group, vehicle was 
given on day 87 (to rats previously given progesterone on 
days 20–30) and progesterone was given on day 88 (to another 
group of rats previously given vehicle on days 20–30).
statistical analyses
For repeated progesterone administration (Figures 1–4), 
data were analyzed using a repeated measures two-way 
analysis of variance. A repeated measures one-way analysis Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Progesterone (4 mg/kg, i.p., n = 8, treatment on days 0–10)
Vehicle (i.p., n = 7, days 0–10)
Figure 2 early treatment on days 0 to 10. 
Notes: Rats were given repeated progesterone treatment 4 mg/kg intraperitoneally (closed circles; n = 8) or peanut oil vehicle (open circles; n = 7) starting one hour after 
cuff implantation surgery, and once daily until day 10. Rats treated with progesterone on days 0–10 showed significantly higher withdrawal thresholds than vehicle-treated 
rats on day 30 (*P , 0.05), 35 (*P , 0.05), 40 (*P , 0.05), and 85 (*P , 0.05). Arrow denotes time of cuff implantation, and shaded area indicates days on which injections 
were given. Data are expressed as means ± standard error of the mean.
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Figure 1 early treatment on days 0 to 4. 
Notes: Withdrawal thresholds of cuff-implanted rats were measured over 87 days to determine the effect of repeated progesterone treatment starting immediately after 
model induction. Rats were implanted with a sciatic nerve cuff on day 0 and given progesterone 4 mg/kg intraperitoneally (closed circles; n = 6) or peanut oil vehicle (open 
circles; n = 7) starting one hour after surgery, and once daily until day 4. Arrow denotes time of cuff implantation, and shaded area indicates the days on which injections 
were given. Data are expressed as means ± standard error of the mean.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Figure 3 Late treatment (days 20 to 23).
Notes: Withdrawal thresholds of cuff-implanted rats were measured to determine the effect of repeated progesterone treatment starting 20 days after model induction. Rats 
were given progesterone 4 mg/kg intraperitoneally (closed circles; n = 6) or peanut oil vehicle (open circles; n = 7) for four days starting on day 20 after cuff implantation. 
no differences in hind paw withdrawal thresholds were observed over the 103-day observation period. Arrow denotes time of cuff implantation, and shaded area indicates 
days on which injections were given. Data are expressed as means ± standard error of the mean.
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Progesterone (4 mg/kg, i.p., n = 6, treatment on days 20–30)
Vehicle (i.p., n = 7, days 20–30)
Figure 4 Late treatment (days 20 to 30).
Notes: Withdrawal thresholds of cuff-implanted rats were measured to determine the effect of repeated progesterone treatment starting 20 days after model induction. 
Rats were given repeated progesterone 4 mg/kg intraperitoneally (closed circles; n = 6) or peanut oil vehicle (open circles; n = 7) starting on day 20 after cuff implantation 
and continued daily until day 30. no differences in hind paw pain withdrawal thresholds were observed over the 84-day observation period. Arrow denotes time of cuff 
implantation, and shaded area indicates days on which injections were given.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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of variance was used for single-dose progesterone testing 
(Figures 5 and 6). The Bonferroni test was used for post hoc 
comparisons, and all analyses were performed using Prism 
4.03 (GraphPad Software, Inc, San Diego, CA).
Results
early treatment: Daily progesterone 
administration starting one hour  
after surgery
Prior to cuff implantation, all rats showed baseline withdrawal 
thresholds of approximately 15 g. One hour after cuff 
implantation surgery, rats were given progesterone 4 mg/kg 
or peanut oil vehicle intraperitoneally. Progesterone or 
vehicle injections were continued daily for the next four days 
(PROG d0–4, VEH d0–4, Figure 1) or 10 days (PROG d0–10, 
VEH d0–10, Figure 2). Figure 1 illustrates the decrease in 
withdrawal thresholds after cuff implantation for both PROG 
d0–4 and VEH d0–4, but the decrease was more gradual in the 
progesterone-treated group. Both groups reached their lowest 
values by day 10. Thereafter, there was a gradual increase 
in withdrawal thresholds in both groups, which leveled off 
by approximately day 35. Although the thresholds for the 
PROG d0–4 group were usually numerically higher than 
VEH d0–4, there was no statistically significant effect of 
treatment [F(1, 99) = 4.72, P = 0.053]. Figure 2 illustrates the 
changes in withdrawal thresholds after cuff implantation and 
treatment for the groups PROG d0–10 and VEH d0–10. The 
main effect of treatment was significant [F(1, 156) = 14.62, 
P = 0.0021]. Post hoc comparisons showed that the PROG 
d0–10 group had significantly higher withdrawal thresholds 
compared with VEH d0–10 on days 30, 35, and 40, and on 
the final day of testing, day 85 (all P values , 0.05). Data 
were analyzed with a repeated measures two-way analysis 
of variance using the Bonferroni post hoc test.
Late treatment: Daily progesterone 
administration starting 20 days  
after surgery
Prior to cuff implantation, all rats showed baseline withdrawal 
thresholds of approximately 15 g. Following cuff implantation, 
withdrawal thresholds decreased to approximately 5 g by 
day 6 in both groups (Figures 3 and 4). Figure 3 illustrates 
the withdrawal thresholds of rats given injections for four 
days starting on day 20, PROG d20–23 and VEH d20–23. 
Thresholds were at approximately 5 g in both groups when 
injections were started. No differences in thresholds were 
observed between rats given the progesterone and the 
vehicle [the main effect of treatment was not significant, 
[F(1, 143) = 0.003, P = 0.96]. Figure 4 shows the withdrawal 
thresholds of rats given injections for a total of 11 days 
starting on day 20, PROG d20–30 and VEH d20–30. There 
were no differences between the two groups on any of the days 
tested over the 84-day observation period (the main effect of 
treatment was not significant, [F(1, 132) = 0.24, P = 0.63]). 
Data were analyzed with a repeated measures two-way 
analysis of variance with the Bonferroni post hoc test.
single-dose effect of progesterone
There were no changes in withdrawal thresholds at 30, 60, 
or 90 minutes after single-dose progesterone administration 
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Figures 5 single-dose treatment. 
Notes: single-dose progesterone 4 mg/kg, intraperitoneally (black columns; n = 6) or peanut oil vehicle (grey columns; n = 6) did not have an effect on paw withdrawal 
thresholds, as measured at 30, 60, and 90 minutes after injection. Data are expressed as means ± standard error of the mean.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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(4 mg/kg, intraperitoneally) compared with baseline, when 
tested on day 4 [F(3) = 1.26, P = 0.32] or day 88 [F(3) = 1.4, 
P = 0.27] after cuff implantation. Vehicle administration was 
also without effect at 30, 60, or 90 minutes after injection, 
when given on day 3 [F(3) = 1.65, P = 0.22] or day 87 
[F(3) = 2.05, P = 0.15]. Results are shown in Figures 5 
and 6. Data were analyzed with a repeated measures one-way 
analysis of variance using the Bonferroni post hoc test.
Discussion
The aim of the present study was to determine if progesterone 
administration in a rat model of peripheral neuropathic 
pain would delay or limit the development of tactile 
hypersensitivity (termed “allodynia” in humans33) in a rat 
model of neuropathic pain. Repeated progesterone treatment 
that started immediately (one hour) after model induction, 
and continued for four days, did not have a significant 
effect on the development of tactile hypersensitivity over a 
12-week observation period. However, when progesterone 
was started immediately after model induction, and continued 
for 10 days, there was a recovery of tactile hypersensitivity in 
the later part of the study, after treatment had ended. Repeated 
progesterone administration (for 4 or 11 days) starting late 
after model induction, ie, on day 20, when hypersensitivity 
was already established, did not have an effect. Also, a 
single injection of progesterone did not have an effect 
on hypersensitivity within 90 minutes of administration 
when given on day 4 or on day 88 after model induction. 
In summary, progesterone promoted the recovery of this 
model of peripheral neuropathic pain, when given as repeated 
injections during the early phase of model development and 
for a sufficient period of time.
Progesterone is synthesized by neurons and glial cells 
of the central and peripheral nervous systems, and has been 
reviewed elsewhere.34–36 Progesterone, like all steroid hormones, 
is derived from cholesterol. Cholesterol is converted to 
progesterone via the intermediate, pregnenolone. Progesterone 
is metabolized in neurons to 5α-dihydroprogesterone which 
can activate the progestin receptor. 5α-dihydroprogesterone 
is converted in a reversible manner by the enzyme 
3α-hydroxysteroid oxidoreductase (3α-HSOR) to 3α,5α-
tetrahydroprogesterone (allopregnanolone) which is a positive 
allosteric modulator of the GABAA receptor. Classical 
intracellular progestin receptors have been localized to several 
regions of the brain, spinal cord, and peripheral neurons.34 
Other targets of progesterone have been identified, ie, the 
sigma 1 receptor,37 the nicotinic acetylcholine receptor,38 
and a family of putative membrane receptors that have been 
cloned.39 It is thought that the diversity of progesterone 
targets is responsible for its pleiotropic effects, which include 
neuroprotection, neuroregeneration, and remyelination.22
Presently there is extensive evidence that progesterone 
and its metabolites have neuroprotective effects in models 
of peripheral neuropathy. In the streptozotocin-induced 
model of diabetes in the rat, treatment with progesterone 
and 5α-dihydroprogesterone for one month reduced myelin 
infolding in the sciatic nerve.40 Chronic treatment with 
progesterone or its derivatives reversed impairments in nerve 
conduction velocity, nociception, skin innervation density, 
and Na+, K+-ATPase activity, and also increased mRNA levels 
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Figure 6 single-dose treatment. 
Notes: single-dose progesterone 4 mg/kg, intraperitoneally (black columns; n = 6) or peanut oil vehicle (grey columns; n = 6) did not have an effect on paw withdrawal 
thresholds, as measured at 30, 60, and 90 minutes after injection. Data are expressed as means ± standard error of the mean.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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of myelin proteins.41 Sameni et al42 showed similar results in 
the same model, in that chronic treatment with progesterone 
improved conduction velocity, edema, axon diameter, 
thickness of myelin, and abnormalities in fiber infolding 
and myelin compaction in the sciatic nerve. Progesterone, 
5α-dihydroprogesterone, and 3α,5α-tetrahydroprogesterone 
reversed many of the changes seen in the aging rat nervous 
system, such as decreased expression of glycoprotein zero 
and peripheral myelin protein 22,43 decreased numbers 
of thin myelinated fibers, as well as myelin infolding 
and irregularities in shape.44,45 In a study of guided nerve 
regeneration, chitosan prostheses containing progesterone 
and pregnenolone improved nerve generation in the rabbit 
facial nerve.46 Repeated treatment with the progestin receptor 
antagonist, mifepristone, starting on postnatal day 1 caused 
a decrease in axon diameter and increased neurofilament 
density.47 Following nerve crush injury, progesterone 
and 5α-dihydroprogesterone treatment increased thermal 
nociceptive thresholds, and restored alterations in myelin 
proteins and in the Na+, K+-ATPase pump induced by the 
injury.32 It is noteworthy that these results were found with 
treatment that was initiated early (starting one day after 
surgery) and given repeatedly, similar to the protocol used 
in the present study.
Beyond its putative role in neuroprotection, other studies 
have reported analgesic or antinociceptive properties. 
For example, recent studies have highlighted a role for 
progesterone and its metabolites in peripheral neuropathic 
pain. Meyer et al48 found an upregulation of 3α-HSOR 
in the spinal cord of rats with sciatic nerve injury caused 
by four loose ligatures. 3α,5α-tetrahydroprogesterone 
administered intrathecally into the spinal cord increased 
thermal and mechanical thresholds. Medroxyprogesterone 
acetate, an antagonist of 3α,5α-tetrahydroprogesterone, had 
the opposite effect. In a rat model of chemotherapy-induced 
neuropathic pain, progesterone, 5α-dihydroprogesterone, 
and 3α,5α-tetrahydroprogesterone prevented and reversed 
vincristine-induced mechanical allodynia and thermal 
hyperalgesia, as well as a number of nerve irregularities.49 
Also, in a vincristine-induced model of neuropathy, long-term 
administration of the anxiolytics, etifoxine, increased the 
rate of recovery.50 Prophylactic administration of etifoxine 
abolished development of neuropathic pain. This effect was 
inhibited by medroxyprogesterone acetate, suggesting the 
effect was due to 3α-neurosteroids. In a spinal cord injury 
model of neuropathic pain, daily progesterone administration 
for approximately one month reversed mechanical and cold 
allodynia.51 The authors found that this was correlated with 
an attenuation of the N-methyl-d-aspartate receptor and 
protein kinase C gamma upregulation, and an increased 
expression of the kappa opioid receptor. This suggests an 
effect of progesterone on key components of the nociceptive 
pathway in the spinal cord.
Conflicting results regarding the effects of progesterone 
in nerve injury models have been observed. It has been 
shown that female rats show higher pain sensitivity than 
males following L5 nerve root ligation.52 Using hormone 
replacements in ovarectomized rats, it was determined that 
progesterone was responsible for this hypersensitivity.53 
The authors suggested that one of the possible explanations 
for this finding is that a physiological dose of progesterone 
was used, while other studies reporting antinocieptive 
effects used supraphysiological doses. In a mouse model 
of spinal nerve ligation, antagonism of the progestin 
receptor and inhibition of the transport protein, peripheral 
benzodiazepine receptor, increased mechanical and thermal 
thresholds.54–56 3α,5α-tetrahydroprogesterone decreased 
the   antinociceptive effect of the peripheral benzodiazepine 
receptor   antagonist, suggesting the effect of the latter was 
partly due to decreasing the activity of the GABAA receptor. 
Species differences may account for the discrepancies 
in results. Also, the acute effect of test compounds was 
determined 2–3 weeks after model induction, which may 
involve additional mechanisms.
Beneficial effects of progesterone on acute and tonic 
models of nociception have also been reported. Acute admin-
istration of progesterone or a peripheral benzodiazepine 
receptor agonist (4-chlordiazepam) decreased nociceptive 
scores in the tail flick test and the formalin test. The effects 
of both drugs were reversed by bicuculline in the tail flick 
test only.57 In a separate study, progesterone and metabolites 
active at the GABAA receptor increased tail flick latencies.58 
In the formalin test, progesterone decreased pain scores 
during the first phase.59 Also in the formalin test, GABAA 
receptor active metabolites of progesterone decreased 
nociceptive scores in the second phase of the test.60 3α,5α-
tetrahydroprogesterone increased nociceptive thresholds to 
thermal and mechanical stimuli in naïve and carageenan-
injected rats, likely through positive allosteric modulation 
of the GABAA receptor.61
Given the multitude of central and peripheral effects 
that have been attributed to progesterone and/or its 
derivatives, it is not surprising that a number of   mechanisms 
of action have been proposed. Progesterone and its Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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derivatives may have neuroprotective, anti-inflammatory, 
and/or antinociceptive effects.62,63 Progesterone and 5α- 
dihydroprogesterone can act through the classical progestin 
receptor to cause an   upregulation of glycoprotein zero, a 
protein important for the structural integrity of the myelin 
sheath. 3α,5α-tetrahydroprogesterone acting as a positive 
allosteric modulator of the GABAA   receptor through a genomic 
mechanism can cause an upregulation of peripheral myelin 
protein 22 which is also critical for   myelination.64 Progesterone 
may directly stimulate the   proliferation of Schwann cells by 
acting on receptors expressed in these cells. These positive 
effects on remyelination may account for recovery of neuronal 
function in models of peripheral neuropathy.
Further investigation is required in order to draw any 
conclusions regarding progesterone’s mechanism(s) of action 
in the present study. Given that progesterone did not have a 
single-dose effect, it may be interpreted that progesterone was 
not acting as an analgesic, and by extrapolation, the effect of 
early repeated administration does not appear to be due to 
an analgesic effect. Because progesterone promotes recovery 
of tactile hypersensitivity with long-term treatment during 
the early phase of model development, it may be postulated 
that progesterone or its active metabolites may be having a 
neuroprotective effect in this model. Remyelination may be 
a plausible cause of recovery, because neuronal degeneration 
is a component of peripheral neuropathy.28
The implication of the present study and previous work 
is that progesterone may be an effective therapy for chronic 
neuropathic pain. In this study, progesterone was effective 
only when started immediately after nerve injury and given 
for a sufficient period of time, suggesting that the timing 
and duration of treatment are both critical for the effect. 
That progesterone alters the development of the model when 
given early, but not late, suggests that there is a window of 
opportunity for treatment. It is well known that treatment of 
traumatic brain injury, spinal cord injury, and stroke must 
be started immediately, and the same may hold true for 
peripheral nerve injuries and insults. Many people with neu-
ropathic pain go for months or even years after injury or onset 
of the disease before being given a correct diagnosis and/or 
  treatment. Therefore, it is not surprising that, in many cases, 
their neuropathic pain is refractory to treatment. Beginning 
an effective regimen of therapy at the earliest possible time, 
and maintaining treatment for a sufficient period, may be 
critical in altering the course of this condition. Therefore, 
early progesterone treatment may prevent the development 
of a chronic unrelenting course of neuropathic pain.
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